[1]刘宇,李冬华,王文娜,等.基于免疫微环境下中医药治疗子宫肌瘤研究进展[J].中国中医药信息杂志,2020,27(11):136-140.[doi:10.19879/j.cnki.1005-5304.202003249]
 LIU Yu,LI Donghua,WANG Wenna,et al.Research Progress in TCM Treatment of Uterine Leiomyoma Based on Immune Microenvironment[J].zhongguo zhongyiyao xinxi zazhi,2020,27(11):136-140.[doi:10.19879/j.cnki.1005-5304.202003249]
点击复制

基于免疫微环境下中医药治疗子宫肌瘤研究进展

参考文献/References:

[1] CHEN L, SUN W, CHEN H, et al. A benign uterine leiomyoma with disturbing appearance[J]. Gynecol Minim Invasive Ther,2019,8(1):44-45.

[2] SHEYN D, BRETSCHNIEDER C E, MAHAJAN S T, et al. Comparison of 30-day complication rates between laparoscopic myomectomy and total laparoscopic hysterectomy for the treatment of uterine leiomyoma in women older than age 40[J]. J Minim Invasive Gynecol,2019,26(6):1076-1082.

[3] SEGARS J H, AL-HENDY A. Uterine leiomyoma:newperspectives on an old disease[J]. Semin Reprod Med,2017,35(6):471-472.

[4] YANG R K, QING Y, JELLOUL F Z, et al. Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies[J]. Oncotarget,2020,11(6):600-618.

[5] WAGNER M, KOYASU S. Cancer immunoediting by innate lymphoid Cells[J]. Trends Immunol,2019,40(5):415-430.

[6] NUNES J B, EVERTS B. Metabolic stress triggers immune escape by tumors[J]. Trends Cancer,2019,5(11):656-658.

[7] GARRIDO F, APTSIAURI N. Cancer immune escape: MHC expression in primary tumours versus metastases[J]. Immunology,2019,158(4):255-266.

[8] WALSH S R, SIMOVIC B, CHEN L, et al. Endogenous T cells prevent tumor immune escape following adoptive T cell therapy[J]. J Clin Invest,2019,129(12):5400-5410.

[9] LIU Y, CAO X. Immunosuppressive cells in tumor immune escape and metastasis[J]. J Mol Med (Berl),2016,94(5):509-522.

[10] 陈腾飞,刘清泉.浅述中医“正气”理论[J].环球中医药,2016,9(11):1332-1335.

[11] 张娟.子宫肌瘤的中药临床应用规律及中医证候与体质调查分析[J].光明中医,2017,32(21):3061-3063.

[12] 甄玉花,梁英才,宋阳,等.基于中医传承辅助系统平台的中医治疗子宫肌瘤方剂组方分析[J].新中医,2017,49(7):171-173.

[13] MCCUNE J S. Rapid advances in immunotherapy to treat cancer[J]. Clin Pharmacol Ther,2018,103(4):540-544.

[14] DE PALMA M. The role of the immune system in cancer:From mechanisms to clinical applications[J]. Biochim Biophys Acta, 2016,1865(1):1-2.

[15] 江益平,吴秀,李娜,等.桂枝茯苓胶囊及其活性成分组合物免疫调节活性及其机制研究[J].中国中药杂志,2015,40(15):3068-3071.

[16] 蔡志英,赵丽.平消胶囊联合高强度聚焦超声治疗子宫肌瘤的临床疗效[J].中国临床研究,2019,32(3):398-400.

[17] XU W, ZHONG W, LIU J, et al. Study on anti-tumor effect of total glycosides from radix paeoniae rubra in S180 tumor-bearing mice[J]. Afr J Tradit Complement Altern Med,2013,10(3):580-585.

[18] RAUTELA J, SOUZA-FONSECA-GUIMARAES F, HEDIYEH-ZADEH S, et al. Molecular insight into targeting the NK cell immune response to cancer[J]. Immunol Cell Biol,2018,96(5):477-484.

[19] ZITVOGEL L, KROEMER G. Unchaining NK cell-mediated anticancer immunosurveillance[J]. Nat Immunol,2016,17(7):746-747.

[20] 刘慰华,张竞之,刘少军,等.黄芪含药血清对NK细胞活性及KLRK1表达的影响[J].现代生物医学进展,2014,14(24):4637-4640.

[21] 曹发昊,王艳萍.党参总皂苷纳米乳对小鼠免疫功能的影响[J].西北农林科技大学学报(自然科学版),2019,47(5):125-131.

[22] 王颜佳.茯苓抗肿瘤、免疫调节药理作用研究及应用[J].海峡药学,2014,26(5):16-18.

[23] SEYA T, TAKEDA Y, TAKASHIMA K, et al. Adjuvant immunotherapy for cancer:both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy[J]. Proc Jpn Acad Ser B Phys Biol Sci,2018,94(3):153-160.

[24] 寇露露,刘海霞,邵妤,等.三棱、莪术抗肿瘤生物活性研究[J].吉林中医药,2017,37(7):722-724.

[25] 汲广全,陈仁琼,郑建仙.白术多糖对树突状细胞表型及功能成熟的影响[J].食品科学,2015,36(3):207-211.

[26] 秦延军,杨树宝,孙朋,等.中药多糖对巨噬细胞和树突状细胞免疫调节作用的研究进展[J].中国兽药杂志,2018,52(2):72-77.

[27] AIPIRE A, MAHABATI M, CAI S, et al. The immunostimulatory activity of polysaccharides from Glycyrrhiza uralensis[J]. Peer J,2020,8:e8294.

[28] AHMETLIC F, RIEDEL T, HOMBERG N, et al. Regulatory T Cells in an endogenous mouse lymphoma recognize specific antigen peptides and contribute to immune escape[J]. Cancer Immunol Res,2019,7(4):600-608.

[29] MUNN D H, SHARMA M D, JOHNSON T S. Treg destabilization and reprogramming:implications for cancer immunotherapy[J]. Cancer Res,2018,78(18):5191-5199.

[30] ZHANG R H, LIU Z K, YANG D S, et al. Phytochemistry and pharmacology of the genus Leonurus:The herb to benefit the mothers and more[J]. Phytochemistry,2018,147:167-183.

[31] DENG X, FU Y, LUO S, et al. Polysaccharide from Radix Codonopsis has beneficial effects on the maintenance of T-cell balance in mice[J]. Biomed Pharmacother,2019,112:108682.

[32] FRIDMAN W H. From cancer immune surveillance to cancer immunoediting:birth of modern immuno-oncology[J]. J Immunol,2018, 201(3):825-826.

[33] DERMANI F K, SAMADI P, RAHMANI G, et al. PD-1/PD-L1 immune checkpoint:Potential target for cancer therapy[J]. J Cell Physiol,2019,234(2):1313-1325.

[34] 楼姣英,曹颖,金哲.中药对SiHa-CTL-Treg共培养体系中CTL细胞CTLA-4、PD-1蛋白的影响[J].北京中医药大学学报,2014,37(4):227-230.

[35] BADAWY A A. Targeting tryptophan availability to tumors:the answer to immune escape?[J]. Immunol Cell Biol,2018,96(10):1026- 1034.

[36] LIU J B, CHEN D, BAO T T, et al. The anticancer effects of atractylenolide Ⅲ associate with the downregulation of Jak3/ Stat3-dependent IDO expression[J]. Front Pharmacol,2019,10:1505.

[37] 刘宇,李冬华,王文娜,等.理冲汤对异种移植子宫肌瘤小鼠免疫逃逸相关因子的影响[J].中国医药导报,2019,16(13):12-15.

相似文献/References:

[1]于会勇,冯淬灵,陈剑明,等.基于文献的老年肺炎常见证候及证候要素分布特点研究[J].中国中医药信息杂志,2012,19(12):24.[doi:10.3969/j.issn.1005-5304.2012.12.009]
 YU Hui-yong,FENG Cui-ling,CHEN Jian-ming,et al.Distribution Characteristics of Common Syndromes and Syndrome Factors of Senile Pneumonia Based on Literature[J].zhongguo zhongyiyao xinxi zazhi,2012,19(11):24.[doi:10.3969/j.issn.1005-5304.2012.12.009]
[2]孙 燕.中医知识工程研究进展分析[J].中国中医药信息杂志,2010,17(12):5.[doi:10.3969/j.issn.1005-5304.2010.12.003]
 [J].zhongguo zhongyiyao xinxi zazhi,2010,17(11):5.[doi:10.3969/j.issn.1005-5304.2010.12.003]
[3]张晓天,龚鹏.三级医院中医“治未病”社区实践与意义[J].中国中医药信息杂志,2010,17(9):5.[doi:10.3969/j.issn.1005-5304.2010.09.003]
 [J].zhongguo zhongyiyao xinxi zazhi,2010,17(11):5.[doi:10.3969/j.issn.1005-5304.2010.09.003]
[4]王凤兰,罗琼,顾漫.北京地区中医非物质文化遗产代表性传承人现状调查[J].中国中医药信息杂志,2009,16(3):1.
 [J].zhongguo zhongyiyao xinxi zazhi,2009,16(11):1.
[5]张伟娜,裘俭,刘国正,等.全国中医古籍保存与保护现状调查分析[J].中国中医药信息杂志,2009,16(6):1.
 [J].zhongguo zhongyiyao xinxi zazhi,2009,16(11):1.
[6]郑淑美,胡立胜,李友林,等.浅谈中医症状量化的运用[J].中国中医药信息杂志,2008,15(6):89.
 [J].zhongguo zhongyiyao xinxi zazhi,2008,15(11):89.
[7]陈二员.中医在美国的发展历程与现状[J].中国中医药信息杂志,2008,15(7):1.
[8]来齐.化瘀消瘤颗粒剂治疗子宫肌瘤52例疗效观察[J].中国中医药信息杂志,2008,15(7):80.
 [J].zhongguo zhongyiyao xinxi zazhi,2008,15(11):80.
[9]朱晓博,指导:崔蒙.中医临床疗效评价方法学研究思路探讨[J].中国中医药信息杂志,2011,18(4):1.[doi:10.3969/j.issn.1005-5304.2011.04.001]
 [J].zhongguo zhongyiyao xinxi zazhi,2011,18(11):1.[doi:10.3969/j.issn.1005-5304.2011.04.001]
[10]郭玉明,姜淼,吕爱平.中医证候分类研究进展[J].中国中医药信息杂志,2011,18(7):106.[doi:10.3969/j.issn.1005-5304.2011.07.052]
 [J].zhongguo zhongyiyao xinxi zazhi,2011,18(11):106.[doi:10.3969/j.issn.1005-5304.2011.07.052]

备注/Memo

基金项目:国家自然科学基金(81774072、81373812、81073096);北京市自然科学基金(7202015);国家中医药管理局中医药传承与创新“百千万”人才工程(岐黄工程)全国中医优秀人才研修项目(2017年)

更新日期/Last Update:

2020-10-19